Targeting zDHHC enzymes to treat Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new treatment that targets certain enzymes (zDHHC) to help fight Alzheimer's disease. It is for adults with Alzheimer's who do not have other major health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a clinical diagnosis of Alzheimer's disease.
- You must be between 18 and 80 years old.
- You must be able to give informed consent (understand and agree to join the study).
- You cannot have other neurological (brain or nerve) diseases.
- You cannot have a bleeding disorder or be taking blood thinners.
- You cannot have skin diseases or connective tissue diseases (like lupus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for people with probable Alzheimer's disease. It aims to see if the treatment is safe and effective for patients between 18 and 80 years old.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests new treatments that target amyloid plaques in the brain, which are linked to Alzheimer's disease. It includes both healthy people and those with mild cognitive impairment or mild-to-moderate Alzheimer's, to see if the treatments are safe and how they affect the body.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.